ICOS and cancer: Advanced-stage cancers had decreased levels of ICOS expression, and tumors with high ratios of PD-L1/ICOS, PD-L2/ICOS, or CD276/ICOS expression have a worse prognosis and a worse prognosis for patients with positive lymph nodes (46).